422P Primary lung tumour laterality, molecular characteristics, and prognostic impact in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) in the phase III CASPIAN trial

L. Paz-Ares; B. Resuli; J.W. Goldman; M.C. Garassino; M.R. Garcia Campelo; L. Hendriks; N. Reinmuth; A. La Salvia; A. D'Incecco; A. Tufman; D. Kauffmann-Guerrero; Gabriele Minuti; N. Donner; C. Obrien; Mingchao Xie; Yashaswi Shrestha; P. Chugh; Haiyi Jiang; L. Landi

doi:10.1016/j.esmoop.2026.106736

Key Points

This analysis aimed to compare the efficacy and safety of PD-(L)1 inhibitors in extensive-stage small cell lung cancer.
Conducted a meta-analysis of multiple studies
Compared outcomes between Asian and non-Asian populations
Evaluated efficacy and safety of PD-(L)1 inhibitors
Demonstrated comparable efficacy of PD-(L)1 inhibitors across populations
Identified limitations due to varied study populations and follow-up durations
Highlighted the need for more regional real-world evidence

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Meta-analysis reveals comparable efficacy of PD-(L)1 inhibitors in extensive-stage small cell lung cancer, suggesting implications for treatment across populations.

Abstract

comparisons between subgroups difficult.Limitations of this meta-analysis included heterogeneity of study populations and follow-up durations. Conclusions:This meta-analysis demonstrates the comparability in efficacy and safety of PD-(L)1 inhibitors for 1L ES-SCLC in both Asian and non-Asian pts.More realworld evidence at the regional level will confirm long-term clinical benefits and tolerability in specific pt populations.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Paz-Ares et al. (2026) studied this question.

synapsesocial.com/papers/69be34886e48c4981c672c4d https://doi.org/10.1016/j.esmoop.2026.106736

View Full Paper

Ask AI

Bookmark

Share

422P Primary lung tumour laterality, molecular characteristics, and prognostic impact in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) in the phase III CASPIAN trial

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

422P Primary lung tumour laterality, molecular characteristics, and prognostic impact in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) in the phase III CASPIAN trial

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading